You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease
SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC. Topic: NIAAbstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A biomarker of aging as a predictor of kidney transplant function
SBC: HEALTHSPAN DIAGNOSTICS, LLC Topic: NIAABSTRACT The number of kidney transplant candidates on the waiting list continues to increase each year, while the number of kidney donations remains stagnant. The enduring donor shortage compels clinicians to use kidneys from marginal donors, referred toas expanded criteria donors (ECD). ECD kidneys, obtained primarily from older donors, have a higher risk of delayed graft function and graft loss ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Bullet Proof vascular graft to prevent dialysis access cannulation injury
SBC: Innavasc Medical, Inc. Topic: 400Project Summary Abstract Synthetic arteriovenous grafts AVGs can provide life sustaining vascular access for dialysis patients but are subject to multiple modes of failure and complications related to chronic needle cannulation poor graft identification delayed access and bleeding These graft needle cannulation associated complications translate to millions of dollars in health care expense ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Accelerated discovery of methylation targeted therapeutic development
SBC: Epicypher, Inc. Topic: 102Project Summary Nucleosomes are the fundamental and repeating units of chromatin consisting of DNA wrapped around a histone octamer Alterations in chromatin structure and function dramatically impact downstream gene expression and cellular physiology This epigenetic regulation is controlled by two major modifications histone post translational modifications PTMs such as histone methylation ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Affinity Capture Peptides for Clinical Mass Spectrometric Assays in Plasma
SBC: AFFINERGY, LLC Topic: NIGMSDESCRIPTION (provided by applicant): We will develop the first assay for multiplexed combinations of all 14 Bone Morphogenetic Proteins. Immunoassays are the gold standard for measuring proteins in clinical samples. However these antibody- based tests neither quantitate protein analyte variants, nor multiplex across large numbers of superfamily members. In addition, the availability of polyclona ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget
SBC: DOTY SCIENTIFIC, INC. Topic: NIA? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Aminoglycosides with reduced ototoxicity
SBC: NUBAD LLC Topic: NIAIDPROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
An H/F/X/Y Fast-MAS NMR Probe Particularly for Alzheimer’s and Cancer Research
SBC: DOTY SCIENTIFIC, INC. Topic: 400DESCRIPTION provided by applicant More than of current drugs and a much greater fraction of those in development are fluorinated including such block busters as Prozac Lipitor and Ciprobay Steady progress over the past decade has shown magic angle spinning MAS solid state NMR ssNMR to be arguably the most powerful analytical tool for studying macro molecular structures and their ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
An Integrative Approach to Control Group Creation for Prevention Research
SBC: PREVENTION STRATEGIES, LLC Topic: NIAAADESCRIPTION provided by applicant The goal of this SBIR project is to develop a method for creating algorithmically generated control groups These will be composed of synthetic cases that have two characteristics pretest similarity to whatever prevention treatment group may present itself and patterns of change over time that closely mimic the normal course of alcohol and drug use d ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A noninvasive method for tissue stiffness quantification in small animals with shear wave elastography
SBC: Sonovol, Inc. Topic: NIDDKAbstract Liver fibrosis a hallmark of many liver diseases affects millions of people in America every year and annually kills tens of thousands of these patients Despite very active research efforts there still have been no specific antifibrotic drugs approved by the FDA The liver disease and drug development communities do not currently have well validated low cost easy to use noninvasiv ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health